




The relative strengths and weaknesses of Insys Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Insys Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Insys Therapeutics Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 404%, being 161% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	82,150
Cost of Goods Sold	12,665
Intangible Assets	0
Liabilities, Current	21,081
Liabilities, Non-Current	0
Other Assets	8,281
Other Compr. Net Income	0
Other Expenses	20,394
Other Liabilities	0
Other Net Income	-982
Other Revenues	99,289
Property and Equipment	10,127
Research and Development	8,499
Selling, General and Administrative Expense	16,372

Output Variable	Value in 1000 USD
Assets	100,558
Liabilities	21,081
Expenses	57,930
Revenues	99,289
Stockholders Equity	79,477
Net Income	40,377
Comprehensive Net Income	40,377
BaseVar	139,920
ECR before Limited Liability	351%
Economic Capital Ratio	404%